Ingen Technologies' new SMART Nasal Cannula unveiled at Alpha-1 19th National Education Conference

Ingen Technologies, Inc. (IGNT), Manufacturer of the New SMART Nasal Cannula for the Home Care Provider Market and Hospital Market, is Featured Side-by-Side Mid and Large Cap Companies Such as Baxter (BAX) at the Alpha-1 19th Annual National Education Conference

Ingen Technologies, Inc. (Pink Sheets:IGNT), a medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S. and $8 billion globally, unveiled their new SMART Nasal Cannula in Orlando-Florida last week at the Alpha-1 19th Annual National Education Conference.

The Alpha-1 Association is a member-based not-for-profit organization dedicated to identifying those affected by Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improve the quality of their lives through support, education, advocacy and to encourage participation in research. Alpha-1-Antitrypsin Deficiency (Alpha-1) is a genetic disorder that can cause liver and lung disease in children and adults.

"We were very pleased to be an exhibitor and sponsor at this year's conference for Alpha-1. There are hundreds of patient members of the Alpha-1 Association, and many of them attended the conference, along with clinicians and physicians from around the globe. Our new SMART Nasal Cannula was featured and well accepted by the attendees. It is our goal to pick up the pace in supporting the various associations that support patients who require home oxygen therapy and the use of our products," stated Scott R. Sand, CEO and Chairman of the Board.